Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 6, 2024

https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-302053462.html

Corporate presentation will be held on Wednesday, February 14, 2024, at 10:00 a.m. ET

NEW HAVEN, Conn., Feb. 6, 2024 /PRNewswire/ — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, at 10:00 a.m. ET. During this virtual event, Ms. Good along with Lisa Delfini, Chief Financial Officer, will also participate in investor meetings with attendees.  

Read more at prnewswire.com

Related news for (TRVI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.